Patient-Level Exposure to Actionable Pharmacogenomic Medications in a Nationally Representative Insurance Claims Database

Background: The prevalence of exposure to pharmacogenomic medications is well established but little is known about how long patients are exposed to these medications. Aim: Our objective was to describe the amount of exposure to actionable pharmacogenomic medications using patient-level measures amo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchini, Monica L., Aquilante, Christina L., Kao, David P., Martin, James L., Anderson, Heather D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672722/
https://www.ncbi.nlm.nih.gov/pubmed/38003889
http://dx.doi.org/10.3390/jpm13111574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672722/
https://www.ncbi.nlm.nih.gov/pubmed/38003889
http://dx.doi.org/10.3390/jpm13111574

Ejemplares similares